{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:07:28Z","timestamp":1789506448217,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ekir.2017.08.013","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T23:15:16Z","timestamp":1504221316000},"page":"115-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome"],"prefix":"10.1016","volume":"3","author":[{"given":"Howard","family":"Trachtman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie S.","family":"Gipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Somers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathie","family":"Spino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Holzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Overfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayanbola","family":"Elegbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Greka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2017.08.013_bib1","doi-asserted-by":"crossref","unstructured":"Trautmann A, Schnaidt S, Lipska-Zi\u0119tkiewicz BS, et\u00a0al., PodoNet Consortium. Long-term outcome of steroid-resistant nephrotic syndrome in children [e-pub ahead of print]. J Am Soc Nephrol. http:\/\/dx.doi.org\/10.1681\/ASN.2016101121.","DOI":"10.1681\/ASN.2016101121"},{"key":"10.1016\/j.ekir.2017.08.013_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.08.013_bib3","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D\u2019Agati","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.08.013_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.08.013_bib5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00467-015-3062-1","article-title":"Recurrent focal segmental glomerulosclerosis after kidney transplantation","volume":"30","author":"Trachtman","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2017.08.013_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev-physiol-020911-153238","article-title":"Cell biology and pathology of podocytes","volume":"74","author":"Greka","year":"2012","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.ekir.2017.08.013_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ekir.2017.08.013_bib8","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI20402","article-title":"Induction of B7-1 in podocytes is associated with nephrotic syndrome","volume":"113","author":"Reiser","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2017.08.013_bib9","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","article-title":"Abatacept in B7-1-positive proteinuric kidney disease","volume":"369","author":"Yu","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.08.013_bib10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.08.013_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00125-015-3766-6","article-title":"CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease","volume":"59","author":"Bassi","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2017.08.013_bib12","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1681\/ASN.2013050518","article-title":"Role of podocyte B7-1 in\u00a0diabetic nephropathy","volume":"25","author":"Fiorina","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.08.013_bib13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1681\/ASN.2007080836","article-title":"Urinary CD80 excretion increases in idiopathic minimal-change disease","volume":"20","author":"Garin","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.08.013_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/ki.2010.143","article-title":"Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis","volume":"78","author":"Garin","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.08.013_bib15","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00467-017-3613-8","article-title":"Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome","volume":"32","author":"Mishra","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2017.08.013_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.08.013_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12882-015-0094-5","article-title":"Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the FONT clinical trial group","volume":"16","author":"Trachtman","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2017.08.013_bib18","first-page":"388","article-title":"Developing therapeutic \u2018arrows\u2019 with the precision of William Tell: the time has come for targeted therapies in kidney disease","volume":"24","author":"Mundel","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2017.08.013_bib19","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1681\/ASN.2015091002","article-title":"B7-1 blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS","volume":"27","author":"Delville","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.08.013_bib20","article-title":"Abatacept experience in steroid and rituximab-resistant focal segmental glomerulosclerosis","author":"Jayaraman","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ekir.2017.08.013_bib21","first-page":"7137584","article-title":"Successful treatment of focal segmental glomerulosclerosis after kidney transplantation with plasma exchange and abatacept in a patient with juvenile rheumatoid arthritis","author":"Sprenger-M\u00e4hr","year":"2016","journal-title":"Case Rep Transplant"},{"key":"10.1016\/j.ekir.2017.08.013_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00467-014-2957-6","article-title":"CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis","volume":"30","author":"Garin","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2017.08.013_bib23","doi-asserted-by":"crossref","first-page":"F335","DOI":"10.1152\/ajprenal.00510.2015","article-title":"Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?","volume":"310","author":"Novelli","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2017.08.013_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.08.013_bib25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/jcph.121","article-title":"Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease","volume":"53","author":"Roberts","year":"2013","journal-title":"J\u00a0Clin Pharmacol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917303716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917303716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T02:35:07Z","timestamp":1535423707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024917303716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2468024917303716"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2017.08.013","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2017.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}